Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
84 hedge funds and large institutions have $79.1M invested in Zynerba Pharmaceuticals, Inc in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 9 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
11% more funds holding
Funds holding: 76 → 84 (+8)
1% less call options, than puts
Call options by funds: $6.27M | Put options by funds: $6.32M
31% less capital invested
Capital invested by funds: $115M → $79.1M (-$36.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$4.98M |
| 2 |
JP Morgan Chase
New York
|
+$2.51M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.97M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$745K |
| 2 |
Barclays
London,
United Kingdom
|
-$526K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$240K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$227K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$167K |
ZYNE Hedge Fund Activity: Q3 2019 in Review
84 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2019, worth a combined $79.1M — down 31% from $115M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ZYNE positions and 9 closed out — a net gain of 8 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was ETF Managers Group, adding an estimated $4.98M. The largest seller was Group One Trading, cutting an estimated $745K.
- 84 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2019, up from 76 in Q2 2019.
- Funds reported $79.1M of Zynerba Pharmaceuticals, Inc stock for Q3 2019, down 31% quarter-over-quarter.
- 17 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2019 and 9 closed out, a net change of +8 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2019 was ETF Managers Group, an estimated $4.98M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2019 was Group One Trading, an estimated $745K sold.
Based on aggregated 13F filings for Q3 2019.